Literature DB >> 6661993

Difference in chromatin sensitivity to heparin of chronic atrophic gastritis, of carcinoma-free and carcinoma-bearing stomach in comparison with normal gastric mucosa and gastric carcinoma as revealed by flow cytometry.

H Weiss, U Heinz, H J Gütz, W Schälicke.   

Abstract

DNA distribution patterns from gastric mucosal cells corresponding to four groups defined by histological examination were measured by flow cytometry before and after treatment with heparin, a polyanion. Group I comprised normal gastric mucosal cells; group II, chronic atrophic gastric mucosal cells originating from a carcinoma free stomach; group III, chronic atrophic gastric mucosal cells originating from a carcinoma bearing stomach; and group IV, malignant gastric mucosal cells. The heparin concentrations used were 1.25, 1.5, and 5 U/ml cell suspension. Heparin caused increases in fluorescence intensity and in coefficients of variation, which are interpreted as a reflection of alterations in chromatin structure. For the four groups investigated, the heparin-initiated changes were dependent, in varying degree, on concentration and time. Group I showed a much more extensive sensitivity to heparin than group IV. Group II and III reacted similarly to group I or group IV, depending on the source, i.e., either a carcinoma-free stomach or a carcinoma-bearing stomach. Further extension of this method might yield information concerning the real premalignant potential of a specific case of chronic atrophic gastritis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6661993     DOI: 10.1002/cyto.990040313

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  2 in total

1.  Mitotic rate, DNA distribution, and chromatin in situ sensitivity to heparin in breast cancer.

Authors:  H Weiss; H P Brasching; A Bock; F Mauthner; U Peek
Journal:  Breast Cancer Res Treat       Date:  1990-07       Impact factor: 4.872

2.  Flow-cytometrically monitored chromatin in situ testing in the breast cell line H184A1N4.

Authors:  H Weiss; P Langen; U Nitschke; I Thun
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.